Industry
Biotechnology
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Loading...
Open
1.23
Mkt cap
104M
Volume
214K
High
1.24
P/E Ratio
-0.57
52-wk high
3.41
Low
1.09
Div yield
N/A
52-wk low
0.54
Portfolio Pulse from
November 11, 2024 | 6:30 pm
Portfolio Pulse from
November 07, 2024 | 10:30 am
Portfolio Pulse from
November 06, 2024 | 9:15 pm
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 23, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 22, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 8:03 pm
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 12:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.